Skip to main content

Table 2 Distributions of tumor characteristics for categories of HOXB13:IL17BR, MGI, and MGI+HOXB13:IL17BR, and BCI.

From: HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease

 

HOXB13:IL17BR

MGI

MGI+HOXB13:IL17BR

BCI

 
 

Low

(n = 293)

High

(n = 315)

Low

(n = 248)

High

(n = 360)

Low

(n = 248)

Intermediate

(n = 158)

High

(n = 202)

Low

(n = 277)

Intermediate

(n = 139)

High

(n = 192)

Total

(n = 608)

Tumor size (cm)

          

   ≤ 1.0

97 (58%)

71 (42%)

91 (54%)

77 (46%)

91 (54%)

39 (23%)

38 (23%)

96 (57%)

37 (22%)

35 (21%)

168

   1.1 - 2.0

130 (48%)

141 (52%)

105 (39%)

166 (61%)

105 (39%)

77 (28%)

89 (33%)

119 (44%)

62 (23%)

90 (33%)

271

   >2.0

66 (39%)

103 (61%)

52 (31%)

117 (69%)

52 (31%)

42 (25%)

75 (44%)

62 (37%)

40 (24%)

67 (40%)

169

Tumor grade1

           

   Well

95 (66%)

49 (34%)

103 (72%)

41 (28%)

103 (72%)

24 (17%)

17 (12%)

106 (74%)

29 (20%)

9 (6%)

144

   Moderate

133 (51%)

128 (49%)

134 (51%)

127 (49%)

134 (51%)

73 (28%)

54 (21%)

144 (55%)

68 (26%)

49 (19%)

261

   Poor

65 (32%)

138 (68%)

11 (5%)

192 (95%)

11 (5%)

61 (30%)

131 (65%)

27 (13%)

42 (21%)

134 (66%)

203

Tumor size and grade2

          

   Group 1

129 (66%)

66 (34%)

129 (66%)

66 (34%)

129 (66%)

42 (22%)

24 (12%)

134 (69%)

45 (23%)

16 (8%)

195

   Group 2

106 (40%)

156 (60%)

80 (31%)

182 (69%)

80 (31%)

76 (29%)

106 (40%)

93 (36%)

60 (23%)

109 (42%)

262

   Group 3

58 (38%)

93 (62%)

39 (26%)

112 (74%)

39 (26%)

40 (26%)

72 (48%)

50 (33%)

34 (23%)

67 (44%)

151

ER status

           

   Positive

274 (53%)

241 (47%)

237 (46%)

278 (54%)

237 (46%)

140 (27%)

138 (27%)

259 (50%)

119 (23%)

137 (27%)

515

   Negative

19 (20%)

74 (80%)

11 (12%)

82 (88%)

11 (12%)

18 (19%)

64 (69%)

18 (19%)

20 (22%)

55 (59%)

93

PR status

           

   Positive

257 (58%)

184 (42%)

211 (48%)

230 (52%)

211 (48%)

126 (29%)

104 (24%)

239 (54%)

99 (22%)

103 (23%)

441

   Negative

36 (22%)

131 (78%)

37 (22%)

130 (78%)

37 (22%)

23 (19%)

98 (59%)

38 (23%)

40 (24%)

89 (53%)

167

HER2 status

           

   Positive

12 (16%)

62 (84%)

16 (22%)

58 (78%)

16 (22%)

11 (15%)

47 (64%)

23 (31%)

16 (22%)

35 (47%)

74

   Negative

281 (53%)

253 (47%)

232 (43%)

302 (57%)

232 (43%)

147 (28%)

155 (29%)

254 (48%)

123 (23%)

157 (29%)

534

  1. 1As determined by pathologist 1; 2Group 1 (≤ 2.0 cm and well or ≤ 1.0 cm and moderate); Group 2 (>2.0 cm and well, or 1.1 to 2.0 cm and moderate, or ≤ 2.0 cm and poor); Group 3 (>2.0 cm and moderate/poor).
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us